Pennsylvania Jury Orders Takeda to Pay $2 Million in Actos CaseOct 6, 2014
A jury has ordered Takeda Pharmaceuticals to pay more than $2 million to a woman who claimed the company’s diabetes drug Actos (pioglitazone) caused her bladder cancer.
Jurors in state court in Philadelphia deliberated more than five hours before finding that officials of the pharmaceutical company based in Osaka, Japan, failed to properly warn Frances Wisniewski’s doctors about Actos’s bladder cancer risk, Bloomberg News reports. In an interview, the woman’s attorney said Takeda “clearly failed to warn, and it clearly caused her damage.” He added that since his client faces a life of bladder cancer, “it’s a fair verdict.” Studies published in the BMJ and the Canadian Medical Association Journal report the increased likelihood of Actos users developing bladder cancer.
The plaintiff, 79, a retired accountant, is the seventh Actos patient to take a suit to trial. Her case follows a $9 billion verdict earlier this year in Louisiana against Takeda and its marketing partner Eli Lilly & Co. for hiding the drug’s risks. The companies have asked a judge to grant them a new trial in that case, according to Bloomberg News. Kenneth D. Greisman, senior vice president and general counsel for Takeda Pharmaceuticals U.S.A. said the company “respectfully disagrees with the verdict and we intend to challenge this outcome.”
Court records indicate that more than 2,700 Actos suits have been consolidated before U.S. District Judge Rebecca Doherty in Louisiana for pretrial information exchanges. Bloomberg News reports that there are hundreds of claims in state courts in addition to the federal lawsuits.